| Name | Title | Contact Details |
|---|
Country Nurses Inc is a Jefferson, WI-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.
Ainsworth Associates is a Healdsburg, CA-based company in the Business Services sector.
TSMT-Tristate Motor Transit is a Joplin, MO-based company in the Business Services sector.
The Smithers Group, Inc. provides technology-based testing, consulting, information, and compliance services to market sectors in the United Kingdom, the United States, and internationally. It offers environmental testing and regulatory services, such as ecotoxicology, avian toxicology, environmental fate, metabolism, residue, analytical and product chemistry, consulting, and endocrine testing for crop protection, pharmaceutical, industrial chemical, and consumer household industries; and quality and environmental management systems certification services, such as ISP 9001, ISO 14001, ISO 9001, AS 9100, ISO/TS 16949, ISO 13485, and related standards to large, medium, and small clients in several industrial, commercial, manufacturing and service, and government business sectors. The company also provides rubber, plastics, polymer, and composites testing and consulting services for tire, industrial, transportation, consumer, and medical industries; and pre-formulation and formulation, analytical chemistry, pre-clinical and clinical bioanalytical testing, and further drug development support services for pharmaceutical, biotechnology, and consumer healthcare industries. In addition, it offers polymer, chemical, pharmaceutical, ecotoxicology, and life-science related knowledge and information products and events, such as technology and market-based journals and books, national and international conferences, polymer technology training courses, and electronic Web and database products to academic and industrial markets. The Smithers Group, Inc. was founded in 1925 and is based in Akron, Ohio. It has additional offices in Asia, and laboratories in North America and Europe. The company also has locations in Ravenna, Ohio; Brimley, Michigan; Shropshire, United Kingdom; China; Wareham, Massachusetts; Snow Camp, North Carolina; and Horn, Switzerland.